CGON Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.6M
+38.6%
1.2M
+6.8%
1.1M
-53.4%
2.3M
+39.4%
1.7M
Cost of Revenue
2.7M
-32.0%
3.9M
+32.5%
3.0M
-3.5%
3.1M
+94.7%
1.6M
Gross Profit
-1065000
+61.5%
-2768000
-47.3%
-1879000
-151.2%
-748000
-940.4%
89.0K
Operating Expenses
62.2M
-25.6%
83.6M
+29.6%
64.5M
+34.5%
48.0M
-6.4%
51.2M
R&D
39.2M
-28.2%
54.7M
+25.0%
43.7M
+46.0%
30.0M
+7.4%
27.9M
SG&A
23.0M
-20.8%
29.0M
+39.4%
20.8M
+15.5%
18.0M
-22.9%
23.3M
Operating Income
-63249000
+26.8%
-86401000
-30.1%
-66389000
-36.3%
-48700000
+4.8%
-51129000
EBITDA
-62094000
+27.4%
-85551000
-30.5%
-65548000
-37.0%
-47851000
+5.6%
-50713000
Net Income
-56891000
+28.0%
-79056000
-31.3%
-60202000
-45.7%
-41309000
+5.7%
-43808000
EPS (Basic)
$-0.64
+28.9%
$-0.90
-26.8%
$-0.71
-36.5%
$-0.52
+8.8%
$-0.57
EPS (Diluted)
$-0.64
+28.9%
$-0.90
-26.8%
$-0.71
-36.5%
$-0.52
+8.8%
$-0.57
Shares (Diluted)
88.9M
+0.8%
88.2M
+4.4%
84.5M
+5.6%
80.1M
+4.4%
76.7M
CG Oncology (CGON) — Financials